Media Thread, page-11533

Godiva. Agreed. Sounds like at least one partnership coming soon. Quite possibly more. It’s interesting to listen to her in this interview. The interviewer has been able to get very simple but detailed answers and explanations, LC like many highly intelligent educated people is very efficient with her words. She often speaks in dot points leaving the listener to fill in the gaps. Which could be daunting without a very detailed knowledge of the companies complex programs. The information given today pads out the recent announcements. It’s very obvious that LC and the IMU team are extremely happy and bullish about their progress so far.

The Azer-Cel program is definitely ready to partner out right now. They have the data needed for BP to commit. This is a confirmation trial. ie . Just repeating the first trial to proved it wasn’t a statistical aberration. It’s more than 99% certain of success.

She kept pushing Azer-Cel to the front of conversation today. It’s highly likely that a partnership deal is close . Probably got heads of agreement already nutted out.

In my view it’s most unlikely that IMU would ever contemplate taking Azer-Cel to market. After watching NEU licence Trofinitide out to ACAD, it’s easy to understand the value a good partner brings. ACAD has done some serious work and invested heavily in the launch of Trofinitide to make it a success. IMU simply does not have the grunt needed to do the heavy lifting required here.

But for investors here it’s very exciting. NEU went from $1 to $26 with serious cash flows from this deal. The BOD at IMU are well aware of how successful this model has been for NEU. With all the programs IMU has on the go, a similar deal for IMU will allow IMU to laser focus on what they do best, developing cancer cures!